Condition: Critically Ill · Continuous Renal Replacement Therapy · Infections · Sponsor: University Hospital Muenster
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
This description comes directly from the study's public registry record.
Alexander Zarbock, MD · +49-251-8347252 · zarbock@uni-muenster.de
Melanie Meersch-Dini, MD · +49-251-47255
Always discuss trial participation with your own doctor first.
| Univ.-Klinik Innsbruck | Innsbruck, Austria | Recruiting |
| Universidade de São Paulo | São Paulo, Brazil | Recruiting |
| Universitätsklinikum Erlangen-Nürnberg, Abteilung für Nephrologie und Hypertensiologie | Erlangen, Germany | Recruiting |
| Kliniken Maria Hilf, Klinik für Anästhesiologie und Operative Intensivmedizin | Mönchengladbach, Germany | Recruiting |
| University Hospital Muenster | Münster, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05450185